MPM Bioventures III QP LP

This profile gathers the share dealings of MPM Bioventures III QP LP across 7 companies, led by Somaxon Pharmaceuticals, Inc., Pharmasset Inc and Humanigen, Inc. The record holds 54 filings, for trades running from 9 January 2007 to 5 February 2013.

The open-market side counts 7 purchases for €15.2M alongside 22 sales for €2.9M. The net balance comes to €12.3M on the buying side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 2 share grants.

Half of the purchases are above €2.1M and half below.

On 7 February 2013 came the latest disclosure, a transaction in Humanigen, Inc. The last purchase on record was published on 9 July 2009, which is 6,331 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.